Leap Therapeutics, Inc. (LPTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.77. It has a SharesGrow Score of 66/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of LPTX = $1.98 (+157.3% from the current price, the stock appears undervalued). Analyst consensus target is LPTX = $6 (+614.7% upside).
Valuation: LPTX trades at a trailing Price-to-Earnings (P/E) of -2.9 (S&P 500 average ~25).
Net income is $5M, growing at +25%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $38,000 against $154M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 35.56 (strong liquidity). Debt-to-assets is 0%. Total assets: $163M.
Analyst outlook: 3 / 4 analysts rate LPTX as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).
